Pictet Asset Management Holding SA Has $2.53 Million Position in GRAIL, Inc. $GRAL

Pictet Asset Management Holding SA lifted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 30.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 53,284 shares of the company’s stock after purchasing an additional 12,358 shares during the period. Pictet Asset Management Holding SA owned 0.13% of GRAIL worth $2,526,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GRAL. Royal Bank of Canada raised its position in GRAIL by 17.7% in the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after acquiring an additional 623 shares during the period. NewEdge Advisors LLC lifted its stake in shares of GRAIL by 390.3% during the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after acquiring an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in GRAIL by 37.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock valued at $2,362,000 after acquiring an additional 25,177 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in GRAIL by 115.7% in the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after acquiring an additional 42,675 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GRAL shares. Wolfe Research started coverage on GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Piper Sandler raised their target price on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Mizuho initiated coverage on shares of GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective on the stock. Finally, Robert W. Baird set a $70.00 price objective on shares of GRAIL in a research note on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $67.00.

Insider Activity

In related news, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares of the company’s stock, valued at $13,012,596.48. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 232,464 shares of company stock worth $11,621,242 over the last quarter. 1.83% of the stock is owned by insiders.

GRAIL Stock Performance

NASDAQ GRAL opened at $69.11 on Monday. GRAIL, Inc. has a 12 month low of $29.95 and a 12 month high of $118.84. The stock has a 50-day simple moving average of $62.41 and a 200 day simple moving average of $70.49. The company has a market capitalization of $2.97 billion, a PE ratio of -6.66 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. The firm had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. As a group, sell-side analysts predict that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: Multiple law firms announced or reiterated class-action claims against GRAIL, saying investors who bought shares between May 13, 2025 and February 19, 2026 may have losses stemming from alleged misrepresentations about trial results and the February 20, 2026 stock collapse. Article Title
• Negative Sentiment: Several firms reminded shareholders of the August 4, 2026 lead-plaintiff deadline, keeping investor attention focused on litigation risk and the possibility of further legal costs or reputational damage for GRAIL. Article Title
• Neutral Sentiment: Additional firms issued near-identical investor alerts and lawsuit reminders, reinforcing the same legal overhang but not adding new operational or financial developments for the company. Article Title

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.